Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol.
Anti-TNFalpha therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. These drugs are powerful and expensive. A new anti-TNFalpha agent, a nanomolecule comprising a humanized Fab' antibody fragment against TNFalpha with a polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will discuss the construct of this new molecule, data from trials so far, and its potential place in the market place.
Barnes
Theresa
T
Academic Rheumatology, University of Liverpool, UK.
Moots
Robert
R
D061067:Antibodies, Monoclonal, Humanized; D023181:Antimicrobial Cationic Peptides / Q000737:chemistry*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000737:chemistry; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068582:Certolizumab Pegol; D002986:Clinical Trials as Topic / Q000639:trends*; D004337:Drug Carriers / Q000737:chemistry*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage* / Q000737:chemistry*; D050997:Nanomedicine / Q000379:methods / Q000639:trends; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000737:chemistry*
D061067:Antibodies, Monoclonal, Humanized; D023181:Antimicrobial Cationic Peptides; D018501:Antirheumatic Agents; D004337:Drug Carriers; D007140:Immunoglobulin Fab Fragments; C045866:peptide-Gly-Leu-amide; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol